September 14, 2020
Multiple Sclerosis Research to Practice II: High-Efficacy DMTs
Jointly provided by Consortium of Multiple Sclerosis Centers and PlatformQ Health Education, LLC
- Physicians— maximum of 1 AMA PRA Category 1 Credit(s)™
- Nurses— 1 Nursing Contact Hours
- Pharmacists— 1 Contact Hours (0.1 CEUs)
This activity is supported by educational grants from Biogen, Genentech, and Sanofi Genzyme.
Neurologists, primary care physicians, advance practice clinicians, nursing professionals, pharmacists, and other healthcare professionals involved in the care of patients with MS.
- Summarize long-term outcomes of treatment with high-efficacy DMTs in patients with relapsing forms of MS
- Identify for whom and when high-efficacy DMTs are appropriate in consideration of disease activity and patient factor
- Apply research outcomes from registries and current clinical trials to identify and address patient needs with relapsing and progressive forms of MS
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC), and Platform Q Health Education. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Ellen M. Mowry, MD
Professor of Neurology and Epidemiology
Johns Hopkins University
Daniel Ontaneda, MD, MSc
Associate Professor of Neurology
Cleveland Clinic Lerner College of Medicine of Case Western